Current Report Filing (8-k)
10 10월 2014 - 5:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(D)
OF THE SECURITIES AND EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 6, 2014
HANSEN MEDICAL, INC.
(Exact name of registrant as specified in charter)
|
|
|
|
|
Delaware |
|
001-33151 |
|
14-1850535 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
800 East Middlefield Road
Mountain View, California 94043
(Address of principal executive offices and zip code)
Registrants telephone number, including area code: (650) 404-5800
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 4.01 |
Changes in Registrants Certifying Accountant |
The Audit Committee (the Audit
Committee) of the Board of Directors of Hansen Medical, Inc. (the Company) has completed a competitive process to review the appointment of the Companys independent registered public accounting firm for the 2014 fiscal year.
As a result of this process, effective October 6, 2014, the Audit Committee engaged BDO USA, LLP (BDO) as the Companys independent registered public accounting firm. The composition of the Audit Committee remains unchanged as
Marjorie L. Bowen, Michael Eagle and Stephen L. Newman, M.D.
(a) |
Dismissal of Independent Registered Public Accounting Firm |
Effective October 6, 2014, the
Audit Committee approved the dismissal of Deloitte & Touche LLP (Deloitte) as the Companys independent registered public accounting firm.
During the Companys two most recent fiscal years and through the date of this Current Report on Form 8-K (i) there were no
disagreements with Deloitte on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure which, if not resolved to Deloittes satisfaction, would have caused Deloitte to make reference to
the subject matter in connection with their reports on the Companys financial statements for such years; and (ii) there were no reportable events, within the meaning set forth in Item 304(a)(1)(v) of Regulation S-K.
Deloittes audit reports on the Companys financial statements for the past two fiscal years did not contain an adverse opinion or
disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles.
The Company has
provided Deloitte with a copy of the disclosures in this Current Report on Form 8-K and has requested that Deloitte furnish it with a letter addressed to the Securities and Exchange Commission stating whether or not Deloitte agrees with the
statements related to them made by the Company in this report. A letter from Deloitte is attached as Exhibit 16.1 of this Form 8-K.
(b) |
Newly Appointed Independent Registered Public Accounting Firm |
Effective October 6, 2014,
the Audit Committee engaged BDO as the Companys independent registered public accounting firm. In addition, during the Companys two most recent fiscal years and through the date of this Current Report on Form 8-K, neither the Company,
nor any party on the Companys behalf, consulted BDO with respect to (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of the audit opinion that might be rendered on the
Companys financial statements, and no written report or oral advice was provided to the Company that BDO concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting
issue, or (ii) any matter that was subject to any disagreement, as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions thereto, or a reportable event within the meaning set forth in Item 304(a)(1)(v) of
Regulation S-K.
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits.
|
|
|
Exhibit
No. |
|
Description |
|
|
16.1 |
|
Letter to Securities and Exchange Commission from Deloitte & Touche LLP, dated October 9, 2014. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
HANSEN MEDICAL, INC.
(Registrant) |
|
|
|
|
Date: October 9, 2014 |
|
|
|
|
|
/S/ CHRISTOPHER P. LOWE |
|
|
|
|
|
|
Christopher P. Lowe |
|
|
|
|
|
|
Interim Chief Financial Officer |
EXHIBIT INDEX
|
|
|
Exhibit
No. |
|
Description |
|
|
16.1 |
|
Letter to Securities and Exchange Commission from Deloitte & Touche LLP, dated October 9, 2014. |
Exhibit 16.1
October 9, 2014
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-7561
Dear Sirs/Madams:
We have read Item 4.01 of Hansen
Medical, Inc.s Form 8-K dated October 9, 2014, and have the following comments:
|
1. |
We agree with the statements made in Item 4.01 (a) in the Form 8-K. |
|
2. |
We have no basis on which to agree or disagree with the statements made in the first paragraph of Item 4.01 and with the statements made in Item 4.01(b) in the Form 8-K. |
Yours truly,
/s/ Deloitte and Touche LLP
San Francisco, CA
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 7월(7) 2024 으로 8월(8) 2024
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 8월(8) 2023 으로 8월(8) 2024